Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Current Deferred Revenue (2016 - 2022)

Agios Pharmaceuticals' Current Deferred Revenue history spans 10 years, with the latest figure at $2.5 million for Q1 2022.

  • For Q1 2022, Current Deferred Revenue changed N/A year-over-year to $2.5 million; the TTM value through Mar 2022 reached $2.5 million, changed N/A, while the annual FY2019 figure was $61.5 million, 88.06% up from the prior year.
  • Current Deferred Revenue reached $2.5 million in Q1 2022 per AGIO's latest filing, down from $4.7 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $61.5 million in Q4 2019 to a low of $550000.0 in Q1 2018.
  • Average Current Deferred Revenue over 4 years is $15.0 million, with a median of $3.6 million recorded in 2020.
  • Peak YoY movement for Current Deferred Revenue: crashed 98.31% in 2018, then surged 2359.62% in 2019.
  • A 4-year view of Current Deferred Revenue shows it stood at $32.7 million in 2018, then skyrocketed by 88.06% to $61.5 million in 2019, then plummeted by 92.28% to $4.7 million in 2020, then plummeted by 47.35% to $2.5 million in 2022.
  • Per Business Quant, the three most recent readings for AGIO's Current Deferred Revenue are $2.5 million (Q1 2022), $4.7 million (Q1 2020), and $61.5 million (Q4 2019).